Form 4: Xenon Pharmaceuticals Director Equity Update

Director Gary Patou exercised restricted share units and received new equity grants in Xenon Pharmaceuticals.

Summary

• Director Gary Patou acquired 2,645 common shares through the vesting of restricted share units (RSUs) on June 1, 2026.
• The reporting person was granted 10,507 share options with an exercise price of $53.46 on June 3, 2026.
• An additional 1,593 RSUs were granted to the director on June 3, 2026.
• Following these transactions, the director holds 26,218 common shares directly and 4,902 shares indirectly via a family trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director equity compensation.

Positives

• Alignment of director interests with shareholders through increased equity ownership.
• Standard equity compensation structure for board members.

Negatives

• None identified.

Risks

• Market price volatility affecting the value of equity-based compensation.

Future Outlook

The newly granted equity awards are scheduled to vest on the earlier of June 1, 2027, or the day before the 2027 annual meeting of shareholders.

Industry Context

StockSavvy.ai notes that this filing represents routine director compensation activity common in the biotechnology sector, reflecting standard corporate governance practices for equity retention.

Comparison to Industry Standards

• The use of annual RSU and option grants for board members is consistent with standard practices for mid-cap pharmaceutical companies.
• Vesting schedules tied to annual shareholder meetings are a common governance mechanism in the industry.

Related Party Transactions

• The reporting person maintains indirect ownership of 4,902 shares through the Gary & Karen Barbara Patou TTEE Patou Family Trust.

Stakeholder Impact

• Minimal impact on shareholders as these are standard equity compensation grants.

Next Steps

• Vesting of 10,507 share options and 1,593 RSUs on or before June 1, 2027.

Key Dates

Keywords

Xenon Pharmaceuticals, XENE, Form 4, Insider Trading, Equity Compensation, Director Ownership